Topiramate Tablet, Film Coated
Product Images NDC 51655-429

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Topiramate (NDC 51655-429). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northwind Health Company, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (51655 429 52 Master Bottle Label Approval Rev A 09 20)

Label (51655 429 52 Master Bottle Label Approval   Rev A 09 20)
This is a medication label for Topiramate tablets with a strength of 25mg. The National Drug Code (NDC) for the medication is 51655-429-52, and there is a total of 30 tablets in the package. The medication is only available with a prescription (Rx Only). There is some additional text that seems to be garbled due to errors and cannot be accurately interpreted.*
FDA Label Image

Structured Product Formula For Topiramate (Dc0a034e Df8a 4de6 Be65 82ebf72ddb48 01)

FDA Label Image

Structured Product Formula For Topiramate (Dc0a034e Df8a 4de6 Be65 82ebf72ddb48 02)

Structured Product Formula For Topiramate (Dc0a034e Df8a 4de6 Be65 82ebf72ddb48 02)
This text shows the cumulative rates for time to first seizure associated with two different doses of Topiramate (50mg/day and 400mg/day). The chart displays the results indicating that the higher dose has a lower cumulative seizure rate compared to the lower dose. The P-value of the study is 0.0002. The chart also displays a time range (in days) from 50 to 400.*
FDA Label Image

Topiramate Tablets Usp (Dc0a034e Df8a 4de6 Be65 82ebf72ddb48 03)

Topiramate Tablets Usp (Dc0a034e Df8a 4de6 Be65 82ebf72ddb48 03)
The text describes data related to the change in average monthly migraine period rate from baseline to a double-blind phase of a study conducted on participants administered with different doses of Topiramate and Placebo. The data is presented in a table format including sample size and p-values.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.